Exhibitors
& Sponsors
Expand Your Reach
Sponsoring or exhibiting at the Community Oncology Conference is a fantastic way to reach nearly 1,600+ attendees that include oncologists/hematologists, practice managers, nurses, payers, employers, advocacy groups, industry stakeholders and more. By supporting the Conference, you are helping community oncology shape a future where all Americans have access to local, affordable, high-quality cancer care.
There are many sponsorship opportunities available, including exhibiting, hosting an educational workshop, providing scholarships for CPAN advocates or fellows, supporting social functions, Conference materials and giveaways, and much more. We cannot do this without the ongoing support of the community.
THANK YOU
Exhibitors
Executive Platinum
The AmerisourceBergen (AB) Specialty GPOs ION Oncology Network
The AmerisourceBergen (AB) Specialty GPOs ION Oncology Network is the largest oncology-specific GPO and preferred strategic partner for community oncology practices nationwide.
With over 20 years of experience, you can rely on us for more than GPO contracts. In addition to giving you access to the most advanced therapies at competitive rates, our experts take pride in helping member practices tap the potential within their business. Whether you’re interested in uncovering new clinical and operational efficiencies, opening new lines of revenue, or need support navigating the transition to value-based reimbursement—AB Specialty GPOs will be there to help you, every step of the way.
In 1998, Oncology Supply became the exclusive distributor for the ION Oncology Network. For more than 40 years, they have stood side by side with community oncology practices across the United States. With access to the entire AmerisourceBergen network, they improve product access, increase supply chain efficiency and work diligently to support practices in enhancing patient care.
Follow ION
Follow OS
Astellas
Astellas Pharma US, Inc. is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical conducting business in more than 70 countries around the world. Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world. For more information on Astellas, please visit: https://www.astellas.com/us
Follow Us
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com
Follow Us
Bristol Myers Squibb
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
CardinalHealth
Cardinal Health Specialty Solutions empowers community oncology practices to navigate the future of oncology care. Working in close collaboration with each practice, we develop and implement a clear roadmap to meet pressing challenges in a new era. With expert insights, responsive tools and committed support, we enable our customers to deliver high-quality, cost-efficient care and future-proof their practices.
Follow Us
Daiichi-Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.daiichisankyo.us
Flatiron Health®
Flatiron Health® is a healthtech company that marries clinical and data science to improve outcomes for patients today and tomorrow. We translate patient experiences into real-world evidence to advance research and inform policy. Flatiron HC isn’t just a leading EHR. It’s the platform for a better patient experience, a healthier practice and smarter research. We help doctors provide better care for their patients.
Follow Us
Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. For more information, visit FoundationMedicine.com.
Genentech
For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions.
We are headquartered in South San Francisco, California.
Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. For more information on Jakafi® (ruxolitinib), visit hcp.jakafi.com. For more information on MONJUVI® (tafasitamab-cxix), visit monjuvihcp.com. For more information on Pemazyre® (pemigatinib), visit hcp.pemazyre.com.
Follow Us
Janssen
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.
Follow Us
Merck
McKesson
McKesson helps specialty providers run successful businesses by clearing the path for them to focus on patient care. We do this with solutions that make practice management more manageable and our “all in” approach to advocacy, consultancy, and collaboration. We invite you to discover and explore the McKesson difference.
Through The US Oncology Network, we give physician-owned specialty practices hands-on practice management support with the infrastructure, expertise and strength to succeed in today’s competitive healthcare environment.
Follow McKesson
Follow US Oncology Network
Pharmacyclics
For more information about Pharmacyclics LLC, an AbbVie Company, please visit pharmacyclics.com.
Follow Us
Gold
Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive’s goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.
Follow Us
BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics.
Follow Us
Eisai Co., Ltd.
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.
Follow Us
EMD Serono
At EMD Serono, science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. Our employees are dedicated to making a positive difference in the lives of patients and their loved ones. EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.
Fresenius Kabi
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, and we supply the US oncology market with one of the largest injectable oncology portfolios in the industry. We’re now committed to launching a range of biosimilars in the US with our BioSpecialized approach to health care. From the collaborative way we work with health care professionals to how we manufacture and deliver our products, we are committed to going beyond medicines to support patient care.
Follow Us
House Rx
House Rx is a technology-enabled service company focused on helping specialty practices dispense medications directly to their patients and avoid the challenges of using outside specialty pharmacies. We support clinics through the entire dispensing process by equipping them with pharmacist expertise and modern technology. Specialized pharmacy care coordinators and pharmacists are central to our service to ensure world-class patient care and experience. By partnering with practices, we’re able to improve patient outcomes, lower the cost of care, and create a better experience for physicians and care teams.
Ipsen Biopharmaceuticals, Inc
Ipsen Biopharmaceuticals, Inc. is a US affiliate of Ipsen SA, a global biotech company. At Ipsen Biopharmaceuticals, we are focused on developing and providing access to therapies for patients who suffer from extremely difficult-to-treat diseases. For more information on Ipsen in North America, please visit www.ipsenus.com. To report adverse events, call 1-855-463-5127.
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options.
MorphoSys
Founded in 1992 in Germany, MorphoSys is dedicated to making exceptional, innovative biopharmaceuticals to help improve lives of patients suffering from serious diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development.
MorphoSys is headquartered in Planegg, Germany. In 2019, the US head office was established in Boston.
As of July 15, 2021, Constellation Pharmaceuticals is a MorphoSys company.
Together, we are committed to delivering breakthrough therapies that bring hope to life.
Follow Us
Myriad
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the company’s website: www.myriad-oncology.com
Follow Us
OneOncology
OneOncology was founded by community oncologists, for community oncologists, with the mission of improving the lives of everyone living with cancer.
We are a platform of the nation’s leading independent oncology practices consisting of 726 providers, practicing at 260+ sites of care and serving over 421,000 patients per year. We are bringing the latest cancer research and treatment options to patients close to home. OneOncology invests in practices to help them grow within their local markets, diversify across multiple specialties, apply data insights and leverage technology to strengthen performance.
Join the partnership.
Drive the future.
Seagen
Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.
Follow Us
Silver
AbbVie
At AbbVie, we are committed to transforming standards of care for blood cancers while advancing a dynamic pipeline of investigational therapies across many cancer types. Our dedicated team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines for patients. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the most debilitating cancers. For more details, please visit http://www.abbvie.com/oncology.
Follow Us
American Oncology Network, LLC (AON)
American Oncology Network, LLC (AON) is an alliance of physicians and veteran healthcare leaders dedicated to ensuring the long-term success and viability of oncology diagnosis and treatment in community-based settings. It is the fastest growing network of community oncology practices delivering local access to exceptional cancer care. Launched in 2018 by the physicians and administrators from the nations’ largest independent community oncology practice, AON’s network has expanded in three years to include more than 170 providers in 16 states.
AON serves its expanding network of partner practices by providing over 36 years of proven practice management expertise, dedicated end-to-end administrative support, and access to an extensive array of centralized ancillary support services that are challenging to maintain independently, yet so critical to the delivery of true value-based cancer care. Through access to centralized services such as patient financial counseling, revenue cycle management, drug purchasing, payer contracting and IT, as well as enhanced services such as pathology and an oral-oncolytic pharmacy, AON practices have realized significant results in increased productivity and improved operations while providing high quality patient care.
Follow Us
Exact Sciences
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smart solutions providing the clarity to take life-changing action, earlier. Building on the success of the Cologuard®, Oncotype DX®, and Oncotype MAP™ tests, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. For more information, visit www.exactsciences.com or www.OncotypeIQ.com
Follow Us
G1 Therapeutics
G1 Therapeutics, Inc., is a commercial-stage biopharmaceutical company focused on the discovery, development, and delivery of next-generation therapies. The company’s first commercially available product, COSELA™ (trilaciclib), was recently approved by the US Food and Drug Administration.
G1 Therapeutics, Inc., is based in Research Triangle Park, North Carolina. For additional information, please visit www.g1therapeutics.com.
G1 Therapeutics™ and the G1 Therapeutics logo, COSELA™ and the COSELA logo are trademarks of G1 Therapeutics, Inc.
©2021 G1 Therapeutics, Inc. All rights reserved. US-2100170 07/2021
GSK
GSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, oncology cell therapy, tumor cell targeting and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
Follow Us
Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved milestones in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to developing and advancing innovative medicines to prevent and treat life-threatening diseases. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
ã 2022 Gilead Sciences, Inc. All rights reserved.
Follow Us
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers [or solid tumor malignancies]. The company markets a drug for multiple myeloma and diffuse large B Cell lymphoma.
Kite Pharma
For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, transforming cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
Follow Us
LeanTaaS
LeanTaaS: LeanTaaS develops software that increases patient access to medical care by optimizing how health systems use expensive, constrained resources like infusion chairs, operating rooms, and inpatient beds.
iQueue for Infusion Centers: Over 485 infusion sites with over 10,000 chairs, including 80% of the National Comprehensive Cancer Network (NCCN) and more than 50% of National Cancer Institute (NCI) hospitals, rely on iQueue for Infusion Centers to increase access, decrease patient wait time, and lower healthcare delivery costs.
Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at www.novartis.com
Pfizer Oncology
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.
Follow Us
Sanofi
Sanofi is an innovative global healthcare company. We are working to advance transformative therapies to help people with cancer. Our current focus is on multiple myeloma and other blood cancers, skin, prostate, lung, and breast cancers. We take bold steps every day to advance our pipeline and work to find solutions that help address critical gaps in care across a variety of difficult-to-treat cancers.
SCiO
SCIO Management Solutions is a revenue cycle management and consulting firm focused on cancer disease related specialties with extensive knowledge in medical and radiation oncology, diagnostics, and various surgical specialties. We understand the complexity of buy-and-bill medical specialties, value based care models, and provide expertise to improve revenue recovery.
SCIO’s Consulting and Auditing Services not only identify the gaps in a practice’s revenue cycle, but SCIO will correct the errors and refile the corrected claims on behalf of your practice. Our Revenue Recovery Audits are contingency based, so there are no upfront fees and we only collect a percentage of the recovered revenue recognized in the audit that your practice wasn’t aware was missing.
Takeda Oncology
At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization too rapidly meet the needs of the cancer community, optimizing our ability to bring transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches enable us to bring novel medicines to patients worldwide.
For more information, visit www.takedaoncology.com.
Follow Us
The Oncology Institute
Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting.
TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations.
With 80+ employed clinicians and more than 600 teammates in 50 clinic locations and growing, TOI is changing oncology for the better.
Follow Us
Viatris
Viatris empowers people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to improve patient health.
Link to Our Story: https://www.viatris.com/en/about-us/our-story
Zyno Solutions
Zyno Solutions provides cost-effective IV infusion solutions and is dedicated to delivering intelligent infusion systems that provide the highest quality of care and patient safety. We offer large volume infusion pumps, ambulatory infusion pumps, integrated wireless infusion systems and IV accessories. We provide these devices and systems for ambulatory infusion suites, oncology infusion suites, long-term care pharmacies, specialty pharmacies and home care providers.
Follow US
Bronze
Annexus Health
Annexus Health is the leading healthcare technology company that is revolutionizing the patient access journey by delivering innovative solutions, including tech-enabled services, that reduce financial and administrative burdens to improve access, speed, and adherence to critical care.
Follow Us
ASCO
The American Society of Clinical Oncology and the Association for Clinical Oncology (collectively, ASCO) represent nearly 45,000 oncology professionals in every cancer subspecialty who care for people living with cancer. Through research, education, and promotion of high quality and equitable patient care, members work to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
Follow Us
Be The Match (NMDP)
The National Marrow Donor Program® (NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With more than 30 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR® (Center for International Blood and Marrow Transplant Research®)—a collaboration with Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care.
Follow Us
Blueprint Medicines
Blueprint Medicines is a global precision therapy company that aims to invent transformative medicines for people with cancer and hematologic disorders. We are delivering our approved therapies to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.
Patient Services URL: https://www.yourblueprint.com/
Follow Us
Boehringer Ingelheim
At Boehringer Ingelheim, we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.
Follow Us
Care Access
Care Access is a leading decentralized research organization (DRO) that breaks down traditional barriers in clinical research for patients, sponsors, and physicians. Its innovative model brings decentralized trials, Sites On Demand™, Virtual PIs, and Mobile Sites to previously-unreachable patient populations to expand the impact of clinical research. Supported by top pharmaceutical and biotech partners across 20 different therapeutic areas, Care Access is scaling and globalizing its new model for clinical trial delivery, where more physicians and patients can engage in life-saving research to develop new therapies faster. To find out how Care Access is transforming the future of clinical trials, visit www.careaccess.com.
Follow Us
Coherus Biosciences
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. For additional information, please visit www.coherus.com.
Follow Us
CTI Biopharma
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on developing and commercializing pacritinib, our product candidate currently in active late-stage development. We are headquartered in Seattle, Washington.
CuraScript SD
CuraScript SD provides integrated delivery solutions for the safe & efficient distribution of specialty pharmaceuticals & associated medical supplies. We’ve been caring for those who care for more than a quarter of a century by supplying biologics, branded drugs, generics, vaccines, infused medications and ancillary supportive care products to a wide range of medical providers.
Follow Us
CureMD
CureMD’s comprehensive Oncology EMR Solutions transform your administrative and clinical operations. Our All-in-ONE, cloud based integrated platform includes practice management, electronic health records, patient portal and Mobile Apps, making CureMD the prime choice for community cancer centers. Key Features include: NCCN Powered Chemotherapy Regimen Library, ASCO CancerLinQ Certified EMR, Automated Dosage Calculation, Trial Drug Management, ONS Compliant MAR, Integrated Charge Capture, Decision Support System, Provider note templates (H&P, ASCO Survivorship Care Templates), Flow sheets, Advanced Analytics, Safety Alerts, NCI CTCAE Adverse Event documentation, Drug Utilization Forecasting, Drug Cabinet Integration, In-Office POC Lab Device Interfaces (example: Hematology Analyzer), Retail Lab Integration, eRX, ePCS (Controlled Substances), Clearinghouse services (including EDI, ERA, Eligibility).
For more information please contact:
Kris Lutkowski
kris.lutkowski@curemd.com
212-509-6200 x 276
Follow Us
Deciphera
We are a commercial-stage biopharmaceutical company on a mission to deliver transformational medicines to patients. Headquartered in Waltham, MA with research facilities in Lawrence, KS, we develop innovative science to provide hope to people living with cancer. Fueled by our proprietary drug discovery platform, Deciphera’s mission is to discover, develop, and deliver important new medicines to patients for the treatment of cancer. We aim to provide novel treatments for patients through inhibition of protein kinases. We are focused on discovering, developing, and delivering important new medicines to patients for the treatment of cancer. Our commitment to patients is at the center of everything we do. We are dedicated. We are focused. We are motivated.
Patient access url: https://www.decipheraaccesspoint.com/
Follow Us
Epizyme
Epizyme, Inc. is a fully integrated biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through transformative epigenetic medicines. In addition to a robust research and discovery pipeline, Epizyme has one commercial oncology product and is exploring the treatment potential of this therapy in investigational clinical trials focused on other conditions. By focusing on the genetic drivers of disease, Epizyme works to match new medicines with the patients who need them. For more information, visit www.epizyme.com.
EUSA Pharma
EUSA Pharma US LLC is a global biopharmaceutical based in Boston, Massachusetts.
Mission: We Change Lives, Patient by Patient. At EUSA we are committed to transforming the lives of people affected by cancer or rare disease, globally. We continuously strive to uncover opportunities which address gaps across adult and pediatric care – through development opportunities, acquiring, and in-licensing therapies. Helping people with few or no options available is at the heart of everything we do at EUSA. Every day, we are proud to make a difference – building a company around our people, our values, and our mission. We see a need. We work together. We don’t give up.
Follow Us
Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. To ensure you have the latest clinical data, including links to our pivotal trial publications, and important product information, visit our website: www.exelixis.com
Florence
Florence is the leading platform for remote connectivity and electronic document workflow management in clinical research. It is considered the industry standard, with more than 10,000 research sites, sponsors and CROs in 44 countries collaborating on its network. Florence advances clinical trials through software for managing document and data flow between research sites and sponsors. Florence solutions foster 25% faster start-up time and 40% reduced document cycle time, among other benefits. To learn about advancing research through collaboration, visit www.florencehc.com.
Follow Us
Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.
Follow Us
Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.
Follow Us
MacroGenics
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company’s flagship product for the treatment of HER2+ metastatic breast cancer was approved by the US Food and Drug Administration in December 2020.
MacroGenics generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
Follow Us
Natera
Signatera is a personalized ctDNA test for molecular residual disease (MRD) detection and treatment response monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Learn more at natera.com/oncology.
Follow Us
NeoGenomics
NeoGenomics is a premier oncology diagnostics company with a comprehensive oncology menu that includes all testing modalities for solid tumor and hematologic malignancies to help solve the diagnostic, prognostic and predictive questions in cancer care.
Comprehensive diagnostic, prognostic and predictive testing with more than 600 tests covering solid tumor and hematologic malignancies. We offer 26 cancer-specific, multi-methodology assays in targeted and broad-based profiles designed to detect genomic alterations in clinically significant driver genes centered on NGS, FISH, and IHC.
NeoGenomics’ NGS menu includes 17 targeted RNA fusion profiles that detects common and novel fusions partners. We have an NGS assay for pan-cancer that provides single order testing solution for solid tumors and includes 44 genes involved in solid tumor development and progression, and an NGS-based liquid biopsy test that detects actionable genes relevant to the treatment and management of advanced non-small cell lung cancer.
NeoGenomics’ flexible test menu meets the clinical demands for every patient. It’s all part of our mission to save lives through improved patient care.
Follow Us
Ontada
Ontada is an oncology insights and technology business dedicated to transforming the fight against cancer. Part of McKesson Corporation, we support science through our data, technology, and channels, which accelerate innovation for life science companies, support the education of community oncology providers and advance patient care. Together with our partners, we improve the lives of cancer patients.
Follow Us
Optimal Outcomes
Optimal Outcomes is a single-source healthcare facility development company that can take your cancer center project from concept through to completion and final occupancy. We manage and assume responsibility for all aspects of cancer center development including site selection, due diligence, securing entitlements, design & engineering, permitting, construction, and on-going facility management.
Optimal Outcome’s unique approach and experience results in clinically integrated, full-service cancer centers that set the standard for patient care and convenience. In addition to laboratory services, diagnostic imaging, medical oncology, hematological pathology and radiation therapy, our facilities also allow for patient counseling, research programs and educational services.
Follow Us
Patient Point
PatientPoint® is the patient engagement platform more providers trust. From patient acquisition to in-office and hospital engagement to remote care, our innovative, tech-enabled solutions deliver highly relevant, personalized health experiences across the entire patient journey. More than 140k healthcare providers and 500 hospitals trust PatientPoint to help them increase practice efficiencies, enhance the patient experience and improve outcomes. See how we can do the same for you. Learn more at patientpoint.com.
Follow Us
Paxman
The PAXMAN Scalp Cooling System, developed by the Paxman family reduces chemotherapy-induced alopecia (CIA) in cancer patients. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of CIA. Now, the world’s leading manufacturer and supplier of scalp cooling equipment, PAXMAN have close to 4,000 Scalp Cooling Systems installed worldwide.
CIA can compromise a patient’s quality of life, negatively impacting on body image, self-esteem and depriving patients of their privacy. The prospect of CIA sometimes causes patients to refuse treatment.
A proven way of combatting CIA, scalp cooling can result in a high level of retention or completely preserve the hair. For patients, this means the opportunity to regain some control, maintain privacy and encourage a positive attitude towards treatment.
The NCCN® Clinical Practice Guidelines in oncology (Version 1.2019) recommend scalp cooling as a category 2A treatment option for patients with invasive breast cancer and ovarian cancer, fallopian tube cancer and primary peritoneal cancer who are receiving chemotherapy to reduce the incidence of CIA.
The leading professional organisation for medical oncology, European Society for Medical Oncology (ESMO), has updated Clinical Practice Guidelines for Dermatological Toxicities Related to Anticancer Agents to include the recommendation of scalp cooling for the prevention of CIA as a Category IIB recommendation, as does the ‘Guidance for the management of early breast cancer’ by Cancer Australia.
Visit www.paxmanscalpcooling.com for clinical information, www.coldcap.com for the patient guide or e-mail info@paxmanscalpcooling.com
#ChangingTheFaceOfCancer
Follow Us
Pharmacosmos Therapeutics Inc.
Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monoferric® (ferric derisomaltose) injection and through exceptional resources to support this treatment. We are the U.S. affiliate of the Denmark-based Pharmacosmos Group. Please visit us at www.monoferric.com to learn more.
Follow Us
Pierian
Pierian is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care. We believe in the potential of genomics to transform human health, and are working to ensure that communities anywhere can experience the benefits. With advanced interpretation technology connected to the most comprehensive genomic knowledgebase, Pierian empowers providers with genomic insights to fulfill the promise of precision care.
Follow Us
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus in the development and commercialization of innovative products to enhance patient care. Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
Follow Us
Regeneron
Since 2007, Regeneron and Sanofi have collaborated to help people with debilitating and complex conditions that are often difficult to diagnose and treat, using fully-human monoclonal antibodies. Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, rare blood disorders, neurology, immunology and oncology.
© 2022 Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. All rights reserved.
ONC.22.01.0044 2/22
Follow Us
SamaCare
SamaCare has built a platform that oncology practices use, at no cost to the practice, to submit, track, and manage their prior authorizations. SamaCare works with many of the premier community oncology practices in the country, and has been shown to reduce the amount of time practices spend on submitting and tracking prior authorizations by 50% while decreasing turnaround time and increasing approval rates.
Follow Us
Sema4
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.
Follow Us
TailorMed
TailorMed delivers the largest network of provider, pharmacy, foundation, and life sciences organizations in the market that helps secure funding for patients in financial need. TailorMed’s platform serves as its foundation, helping proactively identify patients at financial risk through predictive analytics, and dynamically matching and enrolling them into the right funding programs. By tackling the financial challenges of care delivery, TailorMed helps improve access to care, patient and provider experience, treatment adherence, and financial performance.
Follow Us
Unlimited Systems
Unlimited Systems equips cancer specialist providers with the industry-leading g4-Centricity revenue cycle platform. Our software simplifies management of complex financial transactions, delivers features valued by Institutional service lines and Freestanding centers, and guides effective and efficient financial workflow at the point of service as well as across the business office.
Follow Us
Willow Risk Advisors, Inc
Willow Risk Advisors is an independent insurance brokerage firm specializing in Professional Liability (Malpractice) & Business Insurance. Our combined 50 years of experience in the healthcare professional liability insurance industry has led us in handling some of the most complex risk management programs in the country.
We pride ourselves on the ability to provide innovative solutions and professional expertise in underwriting, risk control and claims management. We work closely with our clients and ask the “right questions” to best understand their risk. Once the client’s needs are clearly understood, our team works to develop the optimal risk management solution.
Follow Us
WCG
WCG accelerates the development of new medical therapies by measurably improving the conduct and quality of clinical trials. Through our industry-wide platform and solutions, we enable sites, biopharmaceutical companies, and CROs to advance the delivery of new treatments and therapies while expanding access and awareness for clinical trials to all patients and health care providers. Our Managed Research Solutions allow sites and institutions to re-imagine the traditional business model for clinical research, giving them access to new trials, faster study starts, better performance, and increased focus on patient care.
Follow Us
THANK YOU
Sponsors
Amgen
At Amgen, we are committed to the relentless pursuit of breakthroughs for cancer patients and their families. Visit AmgenOncology.com to learn more.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com
Follow Us
BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics.
Follow Us
CardinalHealth
Cardinal Health Specialty Solutions empowers community oncology practices to navigate the future of oncology care. Working in close collaboration with each practice, we develop and implement a clear roadmap to meet pressing challenges in a new era. With expert insights, responsive tools and committed support, we enable our customers to deliver high-quality, cost-efficient care and future-proof their practices.
Follow Us
Deciphera
We are a commercial-stage biopharmaceutical company on a mission to deliver transformational medicines to patients. Headquartered in Waltham, MA with research facilities in Lawrence, KS, we develop innovative science to provide hope to people living with cancer. Fueled by our proprietary drug discovery platform, Deciphera’s mission is to discover, develop, and deliver important new medicines to patients for the treatment of cancer. We aim to provide novel treatments for patients through inhibition of protein kinases. We are focused on discovering, developing, and delivering important new medicines to patients for the treatment of cancer. Our commitment to patients is at the center of everything we do. We are dedicated. We are focused. We are motivated.
Patient access url: https://www.decipheraaccesspoint.com/
Follow Us
Integra Connect
Integra Connect is driven to make specialty care practices clinically and financially successful through value-based, precision medicine.
By focusing on both clinical and business outcomes, Integra Connect enables customers across the care continuum — including providers, payers, and life sciences companies — to harness value-based, precision medicine to improve their decision-making, and make a difference in patients’ lives.
Integra Connect solutions are helping to accelerate adoption of value-based, precision medicine through:
- Precision Medicine Solutions for Providers, which help users deliver high quality patient care and experiences, while managing costs.
- Revenue Cycle Management Solutions that help practices boost collections, accelerate the billing process, and find hidden growth potential.
- The Integra Connect Platform, which enables customers to advance research, improve drug development and maximize revenue.
- Population Health Solutions that support provider efforts to identify at-risk patients and populations for proactive intervention, optimize costs and quality performance, and excel under value-based payment models.
- The IntegraCloud EHR, which helps users understand the patient journey, improve work efficiency, integrate care and information flows, and easily analyze and report performance.
- Precision Medicine Solutions for Life Sciences that enable customers to identify opportunities for clinical research and drug development, support pipeline, and launch medicines for the benefit of patients.
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options.
Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.
McKesson
McKesson helps specialty providers run successful businesses by clearing the path for them to focus on patient care. We do this with solutions that make practice management more manageable and our “all in” approach to advocacy, consultancy, and collaboration. We invite you to discover and explore the McKesson difference.
Through The US Oncology Network, we give physician-owned specialty practices hands-on practice management support with the infrastructure, expertise and strength to succeed in today’s competitive healthcare environment.
Follow McKesson
Follow US Oncology Network
NeoGenomics
NeoGenomics is a premier oncology diagnostics company with a comprehensive oncology menu that includes all testing modalities for solid tumor and hematologic malignancies to help solve the diagnostic, prognostic and predictive questions in cancer care.
Comprehensive diagnostic, prognostic and predictive testing with more than 600 tests covering solid tumor and hematologic malignancies. We offer 26 cancer-specific, multi-methodology assays in targeted and broad-based profiles designed to detect genomic alterations in clinically significant driver genes centered on NGS, FISH, and IHC.
NeoGenomics’ NGS menu includes 17 targeted RNA fusion profiles that detects common and novel fusions partners. We have an NGS assay for pan-cancer that provides single order testing solution for solid tumors and includes 44 genes involved in solid tumor development and progression, and an NGS-based liquid biopsy test that detects actionable genes relevant to the treatment and management of advanced non-small cell lung cancer.
NeoGenomics’ flexible test menu meets the clinical demands for every patient. It’s all part of our mission to save lives through improved patient care.
Follow Us
OneOncology
OneOncology was founded by community oncologists, for community oncologists, with the mission of improving the lives of everyone living with cancer.
We are a platform of the nation’s leading independent oncology practices consisting of 726 providers, practicing at 260+ sites of care and serving over 421,000 patients per year. We are bringing the latest cancer research and treatment options to patients close to home. OneOncology invests in practices to help them grow within their local markets, diversify across multiple specialties, apply data insights and leverage technology to strengthen performance.
Join the partnership.
Drive the future.
Pfizer Oncology
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.
Follow Us
rxvantage
RxVantage transforms how medical practices engage with life science resources and expertise. Through automation, customization, and technology, RxVantage gives practices smarter connections to innovative solutions that are powering patient care. Our apps intelligently connect healthcare providers with the precise life science resources that they need, when they need them. As a result, medical practices stay on the cutting edge of patient care without disrupting workflows.
Sanofi
Teva Pharmaceuticals
Teva Pharmaceuticals has been developing and producing medicines for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products.